Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe
Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe, in a Jan. 7, 2019 press release.
IntraStem is a non-viral gene delivery technology that is based on cell penetrating peptides. The intracellular delivery system has been designed to overcome the limitations of current gene therapy vectors. Additionally, as a next-generation approach, the system is capable of delivering a variety of biologics, such as plasmid DNA, mRNA, siRNA, proteins, and antibodies, in various cell types, including hard-to-transfect cells.
“The granting of our first IntraStem patents in the US and Europe adds to the excitement building around our next generation, non-viral transfection technology,” commented Nick Staples, CEO of Locate, in a Jan. 7, 2019 press release. “We are delighted with the comparative performance of IntraStem versus current transfection standards, which has now extended across a wide range of cell types, payloads, and preclinical models. The broad utility of IntraStem opens up a multitude of therapeutic opportunities, including gene editing and cell reprogramming in-vivo. We are presently evaluating new product opportunities in therapy areas where cell and gene therapies may deliver breakthrough and potentially curative benefits to patients."
Source: Locate Bio
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.